SOPHiA GENETICS (NASDAQ:SOPH) Stock: Insider Ross Muken Sells 9,838 Shares

Posted by Francis Steltz on Oct 9th, 2026

SOPHiA GENETICS SA (NASDAQ:SOPH – Get Free Report) CEO Ross Muken sold 9,838 shares of the stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $8.13, for a total transaction of $79,982.94. Following the sale, the chief executive officer owned 660,391 shares in the company, valued at approximately $5,368,978.83. This trade represents a 1.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Ross Muken also recently made the following trade(s):

On Monday, September 21st, Ross Muken sold 422 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $8.33, for a total transaction of $3,515.26.

SOPHiA GENETICS Stock Up 2.1%

SOPHiA GENETICS stock opened at $7.30 on Friday. The firm has a market capitalization of $612.40 million, a P/E ratio of -6.35 and a beta of 0.95. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 0.58. SOPHiA GENETICS SA has a twelve month low of $3.75 and a twelve month high of $8.98. The stock’s fifty day simple moving average is $7.88 and its 200-day simple moving average is $6.15.

SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. The company had revenue of $23.31 million during the quarter, compared to analysts’ expectations of $21.72 million. As a group, equities analysts expect that SOPHiA GENETICS SA will post -0.77 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in SOPH. First Dallas Securities Inc. purchased a new stake in SOPHiA GENETICS during the first quarter worth approximately $50,000. Royal Bank of Canada raised its holdings in SOPHiA GENETICS by 3,130.2% during the first quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock worth $96,000 after purchasing an additional 18,781 shares in the last quarter. AXQ Capital LP acquired a new stake in SOPHiA GENETICS during the second quarter worth approximately $119,000. Silverberg Bernstein Capital Management LLC lifted its position in shares of SOPHiA GENETICS by 8.7% during the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 51,970 shares of the company’s stock worth $257,000 after buying an additional 4,155 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. purchased a new stake in shares of SOPHiA GENETICS during the 2nd quarter worth approximately $567,000. Hedge funds and other institutional investors own 31.59% of the company’s stock.

Key Stories Impacting SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

Positive Sentiment: Myriad Genetics and SOPHiA GENETICS are partnering with AstraZeneca to use prostate cancer technology involving genomic-instability scoring. The agreement provides potential commercial and validation benefits for SOPH by connecting its analytics capabilities with Myriad’s testing expertise and AstraZeneca’s oncology development programs. Myriad, SOPHiA partner with AstraZeneca to use prostate cancer technology
Positive Sentiment: The collaboration reinforces SOPHiA GENETICS’ positioning in cancer genomics and could increase adoption of its cloud-based SOPHiA DDM platform. However, the reports do not disclose financial terms, revenue guidance or a specific near-term contribution, so the immediate earnings impact remains uncertain. SOPHiA GENETICS Partners Myriad Genetics To Advance Prostate Genomic Instability Score Technology
Neutral Sentiment: Several executives and directors, including the CEO, chairman, CFO and CTO, sold shares at approximately $8.04–$8.13. The sales were made under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards, and each insider retained a substantial position. SOPHiA GENETICS insider trading report
Negative Sentiment: The broad group of insider sales totaled roughly $669,000 and may create some near-term selling pressure or investor caution, despite the transactions appearing administrative rather than discretionary bearish bets.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on SOPH shares. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. Zacks Research upgraded shares of SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. BTIG Research increased their price objective on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Finally, HC Wainwright raised their price objective on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $10.00.

Get Our Latest Stock Analysis on SOPH

SOPHiA GENETICS Company Profile

(Get Free Report)

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company’s principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.